No evidence of deterioration of cognition or wellbeing following regimen for medulloblastoma

Takeaway

  • Adults treated for medulloblastoma with radiochemotherapy followed by maintenance chemotherapy were not found to have a deterioration of cognition or health-related quality of life (QoL) at follow up periods from 3 months to 60 months.

Why this matters

    Results suggest this treatment regimen is not associated with detrimental effects on the measures of cognition and wellbeing used, warranting confirmation in a larger trial.

¿Quiere leer más?

Inicie sesión o regístrese para acceder a todo el contenido de Neurodiem.

¿Ya tiene una cuenta? Inicie sesión

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.